MarketPeel
Insider Trading Intelligence
Pricing
…
RC

Rebecca Chambers

VCYT
CHIEF FINANCIAL OFFICER · VERACYTE, INC. · CIK 0001823563
FILING MIX · LIFETIME37%/63%
BUYS
23
SELLS
39
TOTAL VALUE
$9.36M
COMPANIES
3
ACTIVE SINCE
Mar 2021
HOLDINGS NOW
251,025
AVG SELL PX
$40.57
TRADE KIND
SHOWING 62 / 62
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 15 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Rebecca Chambers, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+71.43%-3.24%+0.42%-3.66%-4.03%—
14d14+78.57%-6.55%+0.14%-6.69%-7.71%—
30d14+71.43%-5.66%+0.60%-6.26%-6.81%—
60d14+85.71%-10.62%+1.97%-12.59%-14.19%—
90d14+71.43%-7.68%+2.95%-16.53%-19.96%—
180d14(2 pending)+75.00%-12.69%+7.32%-22.09%-19.76%—
1y14(5 pending)+77.78%-25.36%+8.01%-33.37%-36.71%—
2y14(8 pending)+100.00%-63.25%+3.34%-66.59%-67.06%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VCYT · 173,280 shares · as of Jun 4, 2026
045,13490,267135,401180,53420222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 23 buys / 39 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
1,961$50.09$98.2K173,280Jun 4, 2026Jun 4, 2026 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
1,600$49.28$78.9K175,241Jun 4, 2026Jun 4, 2026 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
3,693$47.80$176.5K176,841Jun 2, 2026Jun 4, 2026 ↗View →
ALMR
ALAMAR BIOSCIENCES, INC.
PURCHASE
140,612——140,612Apr 20, 2026Apr 20, 2026 ↗View →
ALMR
ALAMAR BIOSCIENCES, INC.
SALE
140,612——0Apr 20, 2026Apr 20, 2026 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
13,157——180,534Mar 6, 2026Mar 10, 2026 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
36,181——167,377Mar 6, 2026Mar 10, 2026 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
4,400$35.55$156.4K145,137Mar 4, 2026Mar 6, 2026 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
13,941$36.33$506.5K131,196Mar 4, 2026Mar 6, 2026 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
7,234$36.01$260.5K149,537Mar 2, 2026Mar 4, 2026 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
59,324——168,820Feb 26, 2026Mar 2, 2026 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
12,049$38.75$466.9K156,771Feb 26, 2026Mar 2, 2026 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
4,741$47.25$224.0K109,496Dec 4, 2025Dec 4, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
8,537$46.61$397.9K114,237Dec 4, 2025Dec 4, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
3,384$46.16$156.2K122,774Dec 2, 2025Dec 4, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
7,000$41.00$287.0K126,158Nov 5, 2025Nov 7, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
5,371$30.11$161.7K133,158Sep 2, 2025Sep 4, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
5,370$26.74$143.6K138,529Jun 2, 2025Jun 4, 2025 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
30,200——143,899Mar 6, 2025Mar 10, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
11,070$34.76$384.8K113,699Mar 2, 2025Mar 3, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
11,911$33.84$403.1K124,769Feb 27, 2025Mar 3, 2025 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
23,170——136,680Feb 27, 2025Mar 3, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
527$43.85$23.1K113,510Feb 3, 2025Feb 5, 2025 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
7,000$43.23$302.6K114,037Dec 3, 2024Dec 4, 2024 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
3,464$44.12$152.8K121,037Dec 2, 2024Dec 4, 2024 ↗View →
VCYT
VERACYTE, INC.
SALE10b5-1
10b5-1 plan
15,275$38.34$585.7K124,501Nov 12, 2024Nov 14, 2024 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
3,462$20.75$71.8K143,240Jun 2, 2024Jun 4, 2024 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
4,318——148,891Mar 15, 2024Mar 19, 2024 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
2,189$21.10$46.2K146,702Mar 15, 2024Mar 19, 2024 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
59,856——144,573Mar 6, 2024Mar 8, 2024 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
6,112$24.00$146.7K84,717Mar 2, 2024Mar 5, 2024 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
1,800$26.54$47.8K90,829Dec 2, 2023Dec 5, 2023 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
3,652$26.70$97.5K92,629Sep 2, 2023Sep 6, 2023 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
1,183$26.72$31.6K95,754Jun 2, 2023Jun 6, 2023 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
42,956——42,956Mar 6, 2023Mar 9, 2023 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
26,014——96,937Mar 6, 2023Mar 9, 2023 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
2,726$24.10$65.7K70,923Mar 2, 2023Mar 3, 2023 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
735$29.14$21.4K72,998Dec 2, 2022Dec 6, 2022 ↗View →
VCYT
VERACYTE, INC.
SALE
Chief Financial Officer
3,023$19.18$58.0K73,733Sep 2, 2022Sep 7, 2022 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
36,496——36,496Aug 5, 2022Aug 9, 2022 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
21,404——76,756Aug 5, 2022Aug 9, 2022 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
37,773——37,773Mar 3, 2022Mar 7, 2022 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
20,728——54,728Mar 3, 2022Mar 7, 2022 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
67,000——67,000Jul 19, 2021Jul 20, 2021 ↗View →
VCYT
VERACYTE, INC.
PURCHASEGRANT
Stock grant
34,000——34,000Jul 19, 2021Jul 20, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
PURCHASE
Chief Financial Officer
16,727$6.25$104.5K30,324Jun 24, 2021Jun 25, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
16,727$50.72$848.4K13,597Jun 24, 2021Jun 25, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
16,727——77,745Jun 24, 2021Jun 25, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
PURCHASE
Chief Financial Officer
16,727$6.25$104.5K30,324May 25, 2021May 25, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
16,727$45.11$754.5K13,597May 25, 2021May 25, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
16,727——94,472May 25, 2021May 25, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
16,727——111,199Apr 27, 2021Apr 28, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
8,499$56.33$478.8K21,825Apr 27, 2021Apr 28, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
PURCHASE
Chief Financial Officer
16,727$6.25$104.5K30,324Apr 27, 2021Apr 28, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
8,228$56.89$468.1K13,597Apr 27, 2021Apr 28, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
PURCHASE
Chief Financial Officer
16,727$6.25$104.5K30,324Mar 25, 2021Mar 26, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
13,135$50.16$658.9K13,597Mar 25, 2021Mar 26, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
3,592$49.11$176.4K26,732Mar 25, 2021Mar 26, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
SALE
Chief Financial Officer
16,727——127,926Mar 25, 2021Mar 26, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
PURCHASEGRANT
Stock grant
27,037——27,037Mar 15, 2021Mar 18, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
PURCHASEGRANT
Stock grant
13,597——13,597Mar 15, 2021Mar 17, 2021 ↗View →
OM
OUTSET MEDICAL, INC.
PURCHASEGRANT
Stock grant
27,037——27,037Mar 15, 2021Mar 17, 2021 ↗View →
Other insiders · VCYT
Loading peer insiders…
About this filer
CIK 0001823563
ROLE
Chief Financial Officer
PRIMARY
VCYT
COMPANIES
3
ACTIVE SINCE
Mar 2021
MARKETPEEL · /INSIDER/0001823563DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback